Personalized plan aims to cut opioid use in acute pain patients
NCT ID NCT05905146
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a personalized medication plan (PPP) can help patients with acute musculoskeletal pain stop taking strong opioids sooner, reducing the risk of dependence. Researchers will compare patients who receive the PPP during hospitalization to those who get standard care. The trial involves 200 participants and focuses on shortening opioid treatment duration.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- personalized pharmaceutical plan (educational interview)
- What this could lead to
- If it works, this could provide a simple way to reduce opioid dependence in people with short-term pain.
- What could go wrong
- This is a small, early-stage study with only 200 participants, so results may not apply broadly. The intervention is educational, not a drug, so benefits may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE PATHOLOGY OF THE LOCOMOTOR SYSTEM are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Lille
RECRUITINGLille, France
-
CHU de Nimes
RECRUITINGNîmes, France
-
CHU de ROUEN
RECRUITINGRouen, France